ViAqua Therapeutics Announces $8.25 Million Investment Led by S2G Ventures to Scale RNA-Based Solutions in Aquaculture
Funding will enable ViAqua to bring its first product to market, invest in R&D for future products, and prove the platform’s ability to deliver RNA-based solutions at scale. ViAqua Therapeutics, a biotechnology company and developer of an orally administered RNA-particle platform to promote and improve animal health in aquaculture, announced......